Skip to content
Peptigraph home

DSIP Benefits: Claims vs What Studies Show

Benefits people claim for DSIP, set against what published studies measured, and where no study exists.

Medical review pendingSleep peptideUpdated
Strongest evidence
Human RCT
Human / animal studies
9 / 4
in our evidence file (PubMed search, 11 Oct 2026)
FDA status
Not approved
Off Category 2, 15 Apr 2026

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

DSIP claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
SleepHuman RCT evidence, 4 of 48 / 1Anaesthetic depth (BIS); Sleep efficiency and latency; Overall therapeutic benefitEvidence for sleep
Brain healthHuman RCT evidence, 4 of 41 / 1Daytime alertness; SeizuresNone
Growth hormoneHuman RCT evidence, 4 of 41 / 0Growth hormone and prolactinEvidence for growth hormone

Strongest study per claim: Sleep, European journal of anaesthesiology 2009, PMID 19142086; Brain health, European neurology 1987, PMID 3622582; Growth hormone, Psychoneuroendocrinology 1993, PMID 8475226.

What the studies measured

DSIP outcomes in published studies
OutcomeResultStudy typeSource
Anaesthetic depth (BIS)DSIP lightened anaesthetic depth (higher BIS, less delta rhythm) and raised heart rate; the opposite of the hypnotic effect predicted.Human RCTn = 24European journal of anaesthesiology 2009, PMID 19142086
Growth hormone and prolactinDSIP did not change growth hormone or prolactin secretion.Human controlled trialn = 8Psychoneuroendocrinology 1993, PMID 8475226
Sleep efficiency and latencyPolysomnography showed higher sleep efficiency and shorter sleep latency with DSIP than placebo.Human RCTn = 16Neuropsychobiology 1992, PMID 1299794
Overall therapeutic benefitThe authors concluded short-term DSIP is unlikely to be of major therapeutic benefit in chronic insomnia; subjective sleep quality did not change.Human RCTn = 16Neuropsychobiology 1992, PMID 1299794
Sleep time and clinical significanceSleep improved slightly under DSIP but the authors judged it of little clinical significance.Human controlled trialInternational journal of clinical pharmacology research 1987, PMID 3583493
Night sleepDSIP substantially improved night sleep with the first and with repeated doses.Human controlled trialn = 14European neurology 1987, PMID 3622582
Daytime alertnessDaytime alertness and performance increased significantly.Human controlled trialn = 14European neurology 1987, PMID 3622582
Sleep normalisation in insomniacsFour consecutive injections normalised disturbed sleep in insomniacs in this early series.Human controlled trialNeuropsychobiology 1983, PMID 6689058
Latency and durationSleep induction took about 1 hour to start and effects lasted up to 20 hours.Human controlled trialNeuropsychobiology 1983, PMID 6689058
Total sleep timeMedian total sleep time rose by 59% in the 130 minutes after a morning DSIP infusion versus placebo.Human controlled trialn = 6International journal of clinical pharmacology, therapy, and toxicology 1981, PMID 6895513
Plasma DSIP-like immunoreactivityEndogenous DSIP-like immunoreactivity did not differ significantly between groups.Human observationaln = 30Peptides 1995, PMID 8532601
Sleep duration and qualityLonger, less interrupted sleep with no day-time sedation or other side effects in 6 insomniacs after a single dose.Human uncontrolled trialn = 6Experientia 1981, PMID 7028502
Sleep promotion by DSIP fusion peptideA DSIP fusion peptide restored neurotransmitter imbalance better than DSIP alone and may enhance sleep in insomniac mice.Animal · mouse (not a human result)Frontiers in pharmacology 2024, PMID 39444618
SeizuresDSIP and DSIP-12 reduced seizure incidence, grade and duration in rats and increased delta and theta EEG power.Animal · rat (not a human result)Seizure 2005, PMID 15911358
CSF penetrationDSIP and analogs significantly crossed the blood-CSF barrier in dogs, depending on plasma level, half-life and lipophilicity.Animal · dog (not a human result)Brain research bulletin 1986, PMID 3768731
Clearance and half-lifeDSIP disappeared rapidly from dog plasma, with a mean half-life of 4.0 +/- 0.7 min.Animal · dog, monkey and rat (not a human result)Neuroendocrinology 1984, PMID 6379493
Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR (DSIP[tiab] AND (peptide*[tiab] OR sleep*[tiab])))”: 444 results. PubMed search on 2 Oct 2026 for “("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR (DSIP[tiab] AND (peptide*[tiab] OR sleep*[tiab]))) AND (humans[mh] OR patients[tiab] OR insomnia[tiab] OR volunteers[tiab])”: 108 results. PubMed search on 2 Oct 2026 for “("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR (DSIP[tiab] AND (peptide*[tiab] OR sleep*[tiab]))) AND (half-life[tiab] OR pharmacokinetic*[tiab])”: 3 results. PubMed search on 2 Oct 2026 for “("delta sleep-inducing peptide"[tiab] OR emideltide[tiab]) AND (insomnia[tiab] OR "double-blind"[tiab] OR "clinical trial"[pt] OR "randomized controlled trial"[pt] OR "controlled clinical trial"[pt])”: 27 results.

The sleep claim: small human studies, mostly intravenous, with mixed verdicts

In chronic insomnia patients, DSIP gave weak effects on sleep efficiency and latency, and the authors concluded short-term treatment is unlikely to be of major benefit.[3]

A double-blind crossover study in insomniacs found that the sleep improvement under DSIP was of little clinical significance.[4]

A placebo-controlled study in severe chronic insomniacs reported better night sleep and daytime alertness over repeated nights.[5]

The first human study, in normal volunteers, reported a rise in total sleep time versus placebo within a 130-minute window after infusion.[7]

A small case series of chronic insomniacs reported longer sleep, with the sleep-promoting effect only in the second hour and a slight arousing effect in the first.[9]

The alertness and cognition claim

One human report states DSIP raised daytime alertness and performance in insomniacs.[5]

A multi-study review reports higher alertness and better performance in the awake state, and flags that other psychiatric uses remained to be explored.[6]

During anaesthesia, however, DSIP reduced delta rhythm and raised bispectral index, which the authors read as lightening of anaesthetic depth.[1]

The growth hormone claim has a negative human result

In healthy women, DSIP infusions changed neither growth hormone nor prolactin secretion.[2]

A study of plasma DSIP-like immunoreactivity found no group differences between sleep apnea, narcolepsy and normal controls, so it is not a disease marker.[8]

How much human evidence exists

A PubMed search on 2 Oct 2026 for DSIP terms combined with humans, patients, insomnia or volunteers returned 108 records out of 444 for the peptide overall; a narrower controlled-trial query returned 27.

Calculated from date 2026-10-02; human query count 108; controlled query count 27; total peptide records 444; source web/src/data/evidence/dsip.json searches. Formula: shares = 108 / 444 and 27 / 444

Common questions

Is DSIP proven to work?

The strongest study we summarise for DSIP is human rct evidence, among 13 studies. A trial result is not an approval; see the legal status.

What is DSIP peptide used for?

The cached human studies tested it for chronic insomnia, with doses given in the vein.[4]

What does DSIP do?

In the earliest volunteer study the peptide was well tolerated, with no side effects observed, but no classic sedation either.[7]

More on DSIP

Sources

  1. 1Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia.European journal of anaesthesiology · 2009PMID 19142086Accessed 2 Oct 2026
  2. 2Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women.Psychoneuroendocrinology · 1993PMID 8475226Accessed 2 Oct 2026
  3. 3Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.Neuropsychobiology · 1992PMID 1299794Accessed 2 Oct 2026
  4. 4Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.International journal of clinical pharmacology research · 1987PMID 3583493Accessed 2 Oct 2026
  5. 5Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.European neurology · 1987PMID 3622582Accessed 2 Oct 2026
  6. 6Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep.Neuropsychobiology · 1983PMID 6689058Accessed 2 Oct 2026
  7. 7Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.International journal of clinical pharmacology, therapy, and toxicology · 1981PMID 6895513Accessed 2 Oct 2026
  8. 8Delta sleep-inducing peptide in normal humans and in patients with sleep apnea and narcolepsy.Peptides · 1995PMID 8532601Accessed 2 Oct 2026
  9. 9The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.Experientia · 1981PMID 7028502Accessed 2 Oct 2026
  10. 10Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.Frontiers in pharmacology · 2024PMID 39444618Accessed 2 Oct 2026
  11. 11Antiepileptic activity of delta sleep-inducing peptide and its analogue in metaphit-provoked seizures in rats.Seizure · 2005PMID 15911358Accessed 2 Oct 2026
  12. 12Entry of DSIP peptides into dog CSF: role of physicochemical and pharmacokinetic parameters.Brain research bulletin · 1986PMID 3768731Accessed 2 Oct 2026
  13. 13Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs.Neuroendocrinology · 1984PMID 6379493Accessed 2 Oct 2026
  14. 14PubMed search: ("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR (DSIP[tiab] AND (peptide*[tiab] OR sleep*[tiab]))) (444 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: ("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR (DSIP[tiab] AND (peptide*[tiab] OR sleep*[tiab]))) AND (humans[mh] OR patients[tiab] OR insomnia[tiab] OR volunteers[tiab]) (108 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: ("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR (DSIP[tiab] AND (peptide*[tiab] OR sleep*[tiab]))) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: ("delta sleep-inducing peptide"[tiab] OR emideltide[tiab]) AND (insomnia[tiab] OR "double-blind"[tiab] OR "clinical trial"[pt] OR "randomized controlled trial"[pt] OR "controlled clinical trial"[pt]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: ("delta sleep-inducing peptide"[tiab] OR emideltide[tiab] OR DSIP[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026

Found an error? Report a correction.